FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I multi-center study to evaluate the safety of FT596 when given with
rituximab as relapse prevention in patients who have undergone an autologous hematopoietic
stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.